Single-Cell RNA Sequencing for Tumor-Specific Treg Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying and targeting tumor-specific regulatory T cells (Tregs) in cancer treatment are hindered by the lack of reliable markers and the heterogeneity of Treg populations, making it difficult to selectively manipulate these cells for therapeutic purposes.
Innovation Solution
A method involving single-cell RNA sequencing coupled with T cell receptor profiling is used to classify functional tumor-specific regulatory T cells (FT-Tregs) and identify specific markers, allowing for the selective inhibition of tumor-specific Tregs while preserving effector T cells and healthy tissue Tregs, using biomarkers and therapeutic targets to enhance anti-tumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional Treg markers (CD25, Foxp3) are used for identification, then Treg cells can be detected, but conventional T cells also express these markers upon activation causing overlap and reducing identification precision
Solution Approach 1:
The patent segments the heterogeneous Treg population into distinct functional subsets (FT-Tregs, iT-Tregs, nT-Tregs) based on transcriptomic profiles and TCR characteristics. This segmentation allows precise identification of tumor-specific Tregs by their unique molecular signatures, separating them from conventional T cells and other Treg subsets that express similar surface markers.
Solution Approach 2:
The patent transitions from traditional surface marker-based identification (2D flow cytometry) to single-cell RNA sequencing combined with TCR profiling, adding transcriptomic and receptor-level dimensions to the identification process. This multi-dimensional approach enables discrimination of Treg subsets based on gene expression profiles and TCR clonality, overcoming the limitations of surface marker overlap.
2Productivity
If Treg cells are depleted or inactivated to enhance anti-tumor immunity, then anti-tumor response increases, but selective targeting is difficult due to Treg heterogeneity and lack of unique markers
Solution Approach 1:
The patent applies local quality by identifying specific molecular characteristics (transcriptomic signatures, TCR clonality patterns, tissue-specific gene expression) that are unique to tumor-specific Treg subsets. This allows therapeutic strategies to target only the pathogenic FT-Tregs in the tumor microenvironment while preserving regulatory Tregs in healthy tissues that maintain immune homeostasis.
Solution Approach 2:
The patent uses TCR profiling as an intermediary to trace the clonal relationships and tissue migration patterns of Treg cells. By analyzing TCR sequences and their expression across different tissues (blood, tumor, lymph nodes), the method identifies tumor-specific clones that can be selectively targeted without affecting the broader Treg population.
3Measurement precision
If single-cell RNA sequencing with TCR profiling is performed to identify functional tumor-specific Treg clusters, then selective markers are obtained, but the method complexity and cost increase
Solution Approach 1:
The patent performs preliminary action by conducting single-cell RNA sequencing and TCR profiling on fresh or frozen tissue samples to establish comprehensive transcriptomic and receptor-level characterizations of Treg subsets before therapeutic intervention. This preliminary data generation creates a reference framework that enables subsequent targeted therapies using the identified molecular signatures.
Solution Approach 2:
The patent creates molecular copies or signatures of tumor-specific Treg characteristics (gene expression profiles, TCR sequences) that can be used as biomarkers for diagnosis and as targets for therapy. These molecular copies serve as proxies for the actual cells, enabling non-invasive detection and targeted manipulation without requiring continuous access to the original cells.
Data Source
AI summary
The invention relates to a method of identification of functional disease-specific, in particular tumor-specific, regulatory T cells and markers thereof. The invention also relates to the derived functional tumor-specific regulatory T cells, markers and engineered regulatory T cells and to their use for the diagnosis, prognosis, monitoring and treatment of cancer.